Literature DB >> 35788372

Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.

Amy J Davidoff1, Kaitlin Akif2, Michael T Halpern1.   

Abstract

We reviewed current literature reviews regarding economics of cancer-related health care to identify focus areas and gaps. We searched PubMed for systematic and other reviews with the Medical Subject Headings "neoplasms" and "economics" published between January 1, 2010, and April 1, 2020, identifying 164 reviews. Review characteristics were abstracted and described. The majority (70.7%) of reviews focused on cost-effectiveness or cost-utility analyses. Few reviews addressed other types of cancer health economic studies. More than two-thirds of the reviews examined cancer treatments, followed by screening (15.9%) and survivorship or end-of-life (13.4%). The plurality of reviews (28.7%) cut across cancer site, followed by breast (20.7%), colorectal (11.6%), and gynecologic (8.5%) cancers. Specific topics addressed cancer screening modalities, novel therapies, pain management, or exercise interventions during survivorship. The results indicate that reviews do not regularly cover other phases of care or topics including financial hardship, policy, and measurement and methods. Published by Oxford University Press 2022. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Mesh:

Year:  2022        PMID: 35788372      PMCID: PMC9255923          DOI: 10.1093/jncimonographs/lgac011

Source DB:  PubMed          Journal:  J Natl Cancer Inst Monogr        ISSN: 1052-6773


  171 in total

Review 1.  A systematic literature review of the economic implications of chemotherapy-induced diarrhea and its impact on quality of life.

Authors:  Rosanna Tarricone; Dana Abu Koush; Barbara Nyanzi-Wakholi; Antonieta Medina-Lara
Journal:  Crit Rev Oncol Hematol       Date:  2015-12-29       Impact factor: 6.312

Review 2.  Economic evaluation of pediatric cancer treatment: a systematic literature review.

Authors:  Heidi V Russell; Janki Panchal; Helena Vonville; Luisa Franzini; J Michael Swint
Journal:  Pediatrics       Date:  2012-12-24       Impact factor: 7.124

Review 3.  The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.

Authors:  Solange Peters; Christin Bexelius; Veronica Munk; Natasha Leighl
Journal:  Cancer Treat Rev       Date:  2016-03-15       Impact factor: 12.111

Review 4.  Cost effectiveness of rituximab for non-Hodgkin's lymphoma: a systematic review.

Authors:  Philipp W P Auweiler; Dirk Müller; Stephanie Stock; Andreas Gerber
Journal:  Pharmacoeconomics       Date:  2012-07-01       Impact factor: 4.981

Review 5.  The clinical effectiveness and cost-effectiveness of clinical nurse specialist-led hospital to home transitional care: a systematic review.

Authors:  Denise Bryant-Lukosius; Nancy Carter; Kim Reid; Faith Donald; Ruth Martin-Misener; Kelley Kilpatrick; Patricia Harbman; Sharon Kaasalainen; Deborah Marshall; Renee Charbonneau-Smith; Alba DiCenso
Journal:  J Eval Clin Pract       Date:  2015-07-01       Impact factor: 2.431

6.  Looking for Her (2+): A systematic review of the economic evaluations of Trastuzumab in early stage HER 2 positive breast cancer.

Authors:  Panagiotis Petrou
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2018-10-29       Impact factor: 2.217

Review 7.  Cost-Effectiveness of Drug Treatments for Advanced Melanoma: A Systematic Literature Review.

Authors:  Darío Rubio-Rodríguez; Silvia De Diego Blanco; Maite Pérez; Carlos Rubio-Terrés
Journal:  Pharmacoeconomics       Date:  2017-09       Impact factor: 4.981

8.  An updated systematic review of the cost-effectiveness of therapies for metastatic breast cancer.

Authors:  Anagha Gogate; Jason S Rotter; Justin G Trogdon; Ke Meng; Christopher D Baggett; Katherine E Reeder-Hayes; Stephanie B Wheeler
Journal:  Breast Cancer Res Treat       Date:  2019-01-02       Impact factor: 4.872

Review 9.  Effectiveness of palliative care interventions offering social support to people with life-limiting illness-A systematic review.

Authors:  N Bradley; M Lloyd-Williams; C Dowrick
Journal:  Eur J Cancer Care (Engl)       Date:  2018-03-24       Impact factor: 2.520

Review 10.  Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.

Authors:  T Pavey; M Hoyle; O Ciani; L Crathorne; T Jones-Hughes; C Cooper; L Osipenko; M Venkatachalam; C Rudin; O Ukoumunne; R Garside; R Anderson
Journal:  Health Technol Assess       Date:  2012       Impact factor: 4.014

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.